Trials / Completed
CompletedNCT00391690
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Novartis · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It is the aim of this prospective, single-group, clinical study to assess whether bone parameters can be used as diagnostic tools for early detection of bone metastases in patients with high risk prostate cancer. The usefulness in monitoring zoledronic acid therapy in patients who have developed bone metastases will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic acid | In case of bone metastases: Zoledronic acid every 4 weeks for 3 months. |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2010-12-01
- First posted
- 2006-10-24
- Last updated
- 2016-11-18
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00391690. Inclusion in this directory is not an endorsement.